EXCLUSIVE: US FDA shelves commissioner's voucher program for speedy drug reviews, sources say
The US Food and Drug Administration has shelved the fast-track drug review initiative launched during the Trump administration by former Commissioner Marty Makary. Sources indicate the controversial speedy review program is now dead. The move comes amid reports of agency chaos and arrives ahead of a Senate vote on Overton. The halted program previously allowed for priority review vouchers, generating significant industry discussion and debate before its apparent termination.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ The US Food and Drug Administration has shelved the fast-track drug review initiative launched during the Trump administration by former Commissioner Marty Makary.
What changed
The US Food and Drug Administration has shelved the commissioner's voucher program for speedy drug reviews.
Live updates
-
FDA Shelves Commissioner's Voucher Program for Speedy Drug Reviews
The US Food and Drug Administration has shelved the fast-track drug review initiative launched during the Trump administration by former Commissioner Marty Makary. Sources indicate the controversial speedy review program is now dead. The move comes amid reports of agency chaos and arrives ahead of a Senate vote on Overton. The halted program previously allowed for priority review vouchers, generating significant industry discussion and debate before its apparent termination.
Why it matters
The initiative served as a flagship drug fast-track program under former Commissioner Marty Makary during the Trump administration. The sudden shelving highlights internal agency shifts and preceded an impending Senate vote on Overton. Observers and industry professionals are closely watching how the agency handles pending applications and disclosures following the pause.
What is confirmed
- The US Food and Drug Administration has shelved the fast-track drug review initiative launched during the Trump administration by former Commissioner Marty Makary.
Still unconfirmed
- Reports suggest the agency is also pausing complete response letter disclosures alongside the voucher program.
- The program shuttered entirely just ahead of a Senate vote on Overton.
What to watch next
- The upcoming Senate vote on Overton
- Official statements from the FDA regarding the status of the voucher program
- Further disclosures on agency policy changes under current leadership
confidence 90%Sources used for this update (15)
- consent.yahoo.com — Latest news and current events updates | Yahoo News Singapore
- www.yahoo.com — Yahoo
- srnnews.com — Netanyahu survives another day with unexpectedly clear backing of Israeli Jews
- www.pharmacytimes.com — FDA Approves Tildrakizumab for Adults With Psoriatic Arthritis
- Reuters — EXCLUSIVE: US FDA shelves commissioner's voucher program for speedy drug reviews, sources say
- Fierce Pharma — FDA appears to pause controversial speedy review program, complete response letter disclosures
- STAT — Pharmalittle: We're reading about FDA shelving fast-track review, a Canadian importer arrested, and more
- pharmaphorum — Are Makary's priority review vouchers about to be canned?
- BioSpace — FDA’s commissioner voucher program reportedly shuttered ahead of Senate vote on Overton
- RAPS — Recon: FDA shelves commissioner's voucher program; Eli Lilly gets first GLP-1 weight-loss pill approved in China
- The Independent — FDA quietly shelves Trump’s flagship drug fast-track program amid reports of agency chaos
- Endpoints News — FDA’s speedy voucher program is dead: report
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community